IINN files 6-K on HYLA Blood Sensor clinical study completion

Rhea-AI Filing Summary

Inspira Technologies Oxy B.H.N. Ltd. (IINN) furnished a Form 6-K announcing a press release titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission.”

The Company states that the first three and fifth paragraphs and the “Forward-Looking Statements” section of the press release are incorporated by reference into its Registration Statements on Form F-3 (Nos. 333-266748, 333-284308, 333-289324) and Form S-8 (Nos. 333-259057, 333-277980, 333-285565, 333-290162).

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025 (Report No. 2)

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

 On November 13, 2025, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) issued a press release titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first three and the fifth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-266748, 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565 and 333-290162), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

Exhibit No.
99.1		Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on November 13, 2025, titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission.”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.
Date: November 13, 2025	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

2

FAQ

What did Inspira Technologies (IINN) report in this 6-K?

The Company furnished a press release titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission.”

When was the press release referenced by IINN issued?

It was issued on November 13, 2025.

Which registration statements does IINN incorporate content into?

Selected portions of the press release are incorporated into Form F-3 (333-266748, 333-284308, 333-289324) and Form S-8 (333-259057, 333-277980, 333-285565, 333-290162).

Which parts of the press release are incorporated by reference?

The first three paragraphs, the fifth paragraph, and the “Forward-Looking Statements” section.

What product is mentioned in the IINN press release?

The HYLA™ Blood Sensor.

What is the significance of the clinical study mention for IINN?

The press release title indicates the study is complete and positioned ahead of regulatory submission; detailed results are in the press release.